A cooperative study of sarcoidosis in Asia and Africa: analytic epidemiology

Recent Clinical Features of Intraocular Inflammation in Hokkaido, Japan - Comparison with the Previous Decade

PURPOSE

This study aimed to investigate the clinical features of intraocular inflammation (uveitis) in Hokkaido and to assess the etiology trends in comparison with those of our previous survey.

METHODS

We retrospectively reviewed the medical records of 1,616 new referral uveitis patients (1,020 females and 596 males) in Hokkaido University Hospital between 2004 and 2014.

RESULTS

Sarcoidosis was the most frequent etiology (17.4%), followed by Vogt-Koyanagi-Harada disease (8.1%), Behçet's disease (4.5%), and human leukocyte antigen B27 -associated uveitis (2.5%). The etiologies in 48.7% of the patients were unclassified. Compared to the previous survey between 1994 and 2003, the rate of Behçet's disease decreased and that of sarcoidosis increased. The rates of infectious uveitis and vitreoretinal lymphoma increased.

CONCLUSION

Although the order of the top four etiologies was the same in the two surveys, the rate of sarcoidosis increased and that of Behçet's disease decreased.

Sarcoidosis following specific immunotherapy: more than just coincidence?

Although not yet clear, the etiology of sarcoidosis may be linked to seasonal, environmental and genetic factors; mycobacterial or other infections. To the best of our knowledge there is no data suggesting any connection between the onset of sarcoidosis and specific allergen immunotherapy in the medical literature. During the 11-year period between 1993 and 2005, a total of 91 sarcoidosis cases have been diagnosed at our institution. Out of these, here we present 3 cases of de novo sarcoidosis occurring after receiving specific immunotherapy (SIT) at the same institution (two of which had acquired the disease in Sweden where they had resided for a short time). We suggest that sarcoidosis may occur in patients following (SIT) probably via an abnormal immunological host response to an unknown antigenic trigger.

A retrospective study of cutaneous equine sarcoidosis and its potential infectious aetiological agents

Nine horses from ages 5 to 21 years were diagnosed with cutaneous equine sarcoidosis (ES) over an 18-year period. In addition to skin, the lungs were frequently involved, with other organ systems affected less commonly. A predisposition for thoroughbreds and geldings was noted. Cutaneous lesions and signs included crusts, scales, alopecia and pruritus. These were found at various sites, particularly the legs/thighs/elbows, thorax, neck, face and ventral abdomen. Three horses were euthanized shortly after hospitalization; others survived as long as 12 years. Histopathologic stains, immunohistochemistry and polymerase chain reaction assays on paraffin-embedded cutaneous specimens from eight horses for Mycobacterium spp., Coccidioides immitis, Cryptococcus neoformans, Corynebacterium pseudotuberculosis, and Borrelia burgdorferi were all negative. The aetiology of ES is unlikely microbial and continues to be a diagnosis of exclusion. ES, when limited to the skin, is associated with a good prognosis, with either partial or complete response to glucocorticoid therapy in all the surviving horses.

[Epidemiology of sarcoidosis and its genetic and environmental risk factors]

PURPOSE

Review of the literature on epidemiologic data of sarcoidosis and risk factors.

CURRENT KNOWLEDGE AND KEY POINTS

Epidemiological data show that sarcoidosis is a world-wide disease. Frequency is influenced by multiple predisposition factors. The most important are racial factor, sex, age, familial aggregation, genetic factor and/or infective agent. One of these is insufficiency.

FUTURE PROSPECTS AND PROJECTS

Patent sarcoidosis is revealed when concomitant environmental factors (infective agent, climate, country) and predisposition ones (race, sex familial aggregation) appear together and inducing, in each patient, a particular sarcoidosis.

Sarcoidosis

There have been several new insights into the cause and treatment of sarcoidosis. Studies of genetic variation have shown that specific genetic polymorphisms are associated with increased risk of disease or affect disease presentation. These polymorphisms include variation of MHC and cytokines such as tumour necrosis factor (TNF). Not all investigators have come to the same conclusion, suggesting an interaction of various factors, including the patient's ethnic origin. Treatment of sarcoidosis varies considerably. Patients with symptomatic disease for more than 2-5 years have been of particular interest. Corticosteroids remain the standard of care in such cases, but immunosuppressive drugs have proved steroid-sparing in many patients. New agents, including pentoxifylline, thalidomide, and infliximab have proved useful in selected cases. The effectiveness of these agents seems to lie in their ability to block TNF, especially in the treatment of chronic disease.

Epidemiology of sarcoidosis: new frontiers to explore

Epidemiologic studies have been playing frontier roles to explore determinants of sarcoidosis by observing affected persons with the related population. Since 1990, more than 100 epidemiologic papers have been added to the Medline and PubMed databases. Of them, just a few were dated after March 2001. This article is focused on the papers after that time, referring to a number of previous important epidemiologic studies. The review is arranged according to two major epidemiologic categories: (1) host-related findings such as age, sex, race, familial clustering, and lifestyle; and also (2) time- and space-related findings such as exposures, geographical variation, local clustering, climate and seasonal variation, migration, and time-space clustering (transmission).

Sarcoidosis in developing countries

Sarcoidosis is seen in different parts of India and other developing countries with almost similar frequency as in the West. It was largely due to lack of awareness and non-availability of investigations for diagnosis that the disease was reported to be rare in the past. A combination of clinical, radiologic, and histologic criteria are used to diagnose sarcoidosis. A confident exclusion of other causes of granuloma formation, especially tuberculosis, is required. Absence of mycobacteria and of caseation in the histologic specimens and presence of skin anergy to tuberculin help make a diagnosis. Transbronchial lung biopsy obtained with the help of fiberoptic bronchoscopy is positive in about 80% of patients. Corticosteroids are used to treat patients with symptoms and those showing active organ involvement. Aggressive treatment is required for patients with acute and severe pulmonary, cardiac, ocular, or neurologic involvements.

Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group

Sarcoidosis is a chronic granulomatous disorder of unknown cause, characterized by activation of T-lymphocytes and macrophages. A Case Control Etiologic Study of Sarcoidosis (ACCESS) is a multicenter study designed to determine the etiology of sarcoidosis. The study organization includes 10 Clinical Centers, a Clinical Coordinating Center, specialized Core Laboratories, a Central Specimen Repository, and a Project Office at the National Heart, Lung, and Blood Institute. In addition to etiology, ACCESS will examine the socioeconomic status and clinical course of patients with sarcoidosis. We propose to enroll 720 newly diagnosed cases of sarcoidosis and compare them to 720 age, sex, and race matched controls and follow the first 240 cases for two years. Leads to the etiology of sarcoidosis have come from diverse sources: in clinical laboratory investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation. We describe the rationale for the study design based on genetic, environmental, infectious, and immune dysregulation hypotheses and the methods used for selecting controls. The cause may not prove to be a single, known exposure. Interactions of exposures with genetic predispositions would have important implications for our understanding of immune responses as well as the pathogenesis of sarcoidosis.

Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us?

Textbooks of clinical medicine often begin with "epidemiology" of the disease by describing the distribution of patients' characteristics in terms of age, gender, race, and so on. As a result, many clinicians erroneously think the description of such distribution is a role only for epidemiology. The real role of epidemiology, however, is to search for the determinants of and ways to prevent the disease. In this article, the recent informative papers on the epidemiology of sarcoidosis are reviewed in the light of modern sarcoidology.

Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data

PURPOSE

We sought to describe sarcoidosis mortality in the United States from 1979 through 1991.

METHODS

We analyzed death certificate reports compiled by the National Center for Health Statistics for the period 1979 through 1991.

RESULTS

Of the 26,866,600 people who died during the study period, 9,014 had a diagnosis of sarcoidosis listed on their death certificates. We restricted our study group to 5,791 people who died because of sarcoidosis or one of its complications. Among men, age-adjusted mortality rates increased from 1.3 per 1,000,000 in 1979 to 1.6 per 1,000,000 in 1991, and among women, these rates increased from 1.9 per 1,000,000 in 1979 to 2.5 per 1,000,000 in 1991. Age-adjusted mortality rates were consistently higher among blacks than whites. Age-adjusted mortality rates stratified by race, varied by state. Among whites, the highest rates were in northern states, while among blacks, the highest rates were in the Middle Atlantic and northern Midwestern states.

CONCLUSIONS

Reported mortality due to sarcoidosis varies by region, sex, and race. We cannot determine whether these differences are related to characteristics of the disease, or problems in death certification and coding.

Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature

Forty-nine patients, 30 males and 19 females with acute sarcoid arthritis admitted to three different hospitals in Norway were studied retrospectively. All patients had peripheral arthritis and hilar adenopathy, and 87.8% also presented with erythema nodosum (EN). Mean duration of arthritis was 3.7 months (0.5-12 months), but in 26% of the cases, duration of the inflammatory joint disease exceeded three months. Radiological bony erosions were not seen. Two patients had recurrence of acute sarcoid arthritis, 14 months and 10 years after the initial episode, respectively. Two other patients developed chronic myalgia and fibromyalgia. Four patients, one female and three males, developed chronic pulmonal sarcoidosis. Of these, two patients had simultaneous onset of acute sarcoid arthritis and parenchymal disease while two patients developed chronic lung disease three months after onset of acute sarcoid arthritis. We thus tentatively suggest that although acute sarcoid arthritis is usually a self-limiting joint disease, recurrences may occasionally occur and some cases develop chronic sarcoidosis of the lungs.

Epidemiology of sarcoidosis in the Isle of Man--1: A case controlled study

A case controlled study of 96 cases of sarcoidosis has been carried out in the Isle of Man. Age and sex matched controls were selected at random from the pathology and radiology records, which cover 85% of the resident population, and a second control group was drawn from a tuberculosis register. Special efforts were made to achieve a high level of ascertainment. In this study most cases occurred in young adults. It affected the sexes equally and occurred more frequently in the indigenous Manx population. Thirty eight cases (39.6%) had been in contact with the disease before diagnosis, compared with two (1.2%) of the combined controls. These contacts included members of the same household, colleagues at work, and close friends. A bias may have been introduced as patients would inevitably be more aware of the disease and be more likely to mention previous contact than the controls. Nevertheless, the evidence is considered to support the view that sarcoidosis is a communicable disease.